Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 163Lung Neoplasms 53Neoplasms 14Neoplasm Metastasis 10NSCLC 10Brain Neoplasms 10Carcinoma 9Meningeal Carcinomatosis 6Colorectal Neoplasms 5Bronchial Neoplasms 5Thoracic Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Lung Diseases 3Carcinoma, Squamous Cell 3Breast Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Prostatic Neoplasms 2Noonan Syndrome 2Non Small Cell Lung Cancer Metastatic 2

Interventions

osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Non-Small Cell Lung Cancer With EGFR Mutation × osimertinib × Clear all
NCT06306456 2024-07-08

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Suzhou Genhouse Bio Co., Ltd.

Phase 1/2 Recruiting
94 enrolled
Thoracic

Non-Small Cell Lung Cancer With EGFR Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡